Associate Professor Gopala Rangan

Associate Professor (Conjoint)
Medicine, Westmead Clinical School
The Westmead Institute for Medical Research

Telephone +61 2 9845 6962
Fax +61 2 9633 9351

Website Honours in Medical Sciences at Westmead
Westmead Institute for Medical Research
Westmead Clinical School

Map

Research interests

Polycystic Kidney Disease, Chronic Kidney Disease, Glomerulonephritis

Current projects

Preclinical Research in polycystic kidney disease (PKD)

  1. Role of vitamin D receptor signalling in the progression of polycystic kidney disease
  2. Nuclear factor-kappaBas a therapeutic target in polycystic kidney disease
  3. Cell cycle regulatory proteins as a therapeutic target in polycystic kidney disease

Clinical Research in Autosomal Dominant (AD)PKD and chronic kidney disease (CKD)

  1. Randomised controlled trial to determine the feasibility, safety and efficacy of prescribed water intake to prevent kidney failure due to ADPKD (PREVENT-ADPKD) (recruitment commenced Dec 2015, in progress).
  2. Controlled trial of slowing kidney diseas progression from the inhibition of xanthine oxidase (CKD-FIX) (in progress).
  3. Mulitcenter, open-lab, extension study to evaluate the long-term efficacy and safety of oral tolvaptan tablet regimens in subjects with ADPKD (in progress).

Keywords

Nephrology; Cell biology; Kidney disease; Pharmacology

Clinical Specialty

Nephrology

Selected grants

2016

  • Does Prescribed Fluid Intake Reduce the Progression of kidney failure in ADPKD; Rangan G; DVC Research/Bridging Support Grant.

2014

  • Randomised controlled trial to prevent Kidney Disease due to ADPKD; Rangan G, Harris D; DVC Research/Bridging Support Grant.

2013

  • CKD-FIX: a randomised, controlled trial of allopurinol in the slowing of kidney disease progression; Johnson D, Harris D, Faull R, Palmer S, Boudville N, Badve S, Rangan G, Kanellis J, Walker R, Brown F; National Health and Medical Research Council (NHMRC)/Project Grants.

2010

  • Vitamin D3 receptor signalling to prevent kidney failure due to polycystic kidney disease; Rangan G, Harris D; National Health and Medical Research Council (NHMRC)/Project Grants.

2007

  • Loss of E-cadherin in distal tubule cells as a common pathway for cyst formation in polycystic kidney disease; Rangan G, Harris D; National Health and Medical Research Council (NHMRC)/Project Grants.

2003

  • Regulators of cell cycle as therapeutic drug-targets for cortical tubular hyperplasia in proteinuric renal disease; Rangan G; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Books

  • Harris, D., Elder, G., Kairaitis, L., Rangan, G. (2012). Pocket Guide to Clinical Dialysis. Sydney, Australia: McGraw Hill.

Edited Books

  • Harris, D., Elder, G., Kairaitis, L., Rangan, G. (2005). Basic Clinical Dialysis. Sydney: McGraw-Hill, Medical Pub. Division.

Book Chapters

  • Sud, K., Rangan, G. (2012). Peritonitis and Exit-Site Infections. In David Harris, Grahame Elder, Lukas Kairaitis, Gopala Rangan (Eds.), Pocket Guide to Clinical Dialysis, (pp. 245-255). Sydney, Australia: McGraw Hill.
  • Succar, L., Harris, D., Rangan, G. (2011). Role of the Mammalian Target of Rapamycin (mTOR) Signalling Pathway in Podocytes in Glomerular Disease. In Sharma S. Prabhakar (Eds.), An Update on Glomerulopathies - Etiology and Pathogenesis, (pp. 183-202). Rijeka, Croatia: InTech Publishers.
  • Rangan, G. (2008). Haematuria. In David Harris (Eds.), Clinical Cases in Kidney Disease, (pp. 63-75). Australia: McGraw Hill.
  • Rangan, G., Succar, L. (2008). Rapidly Progressive Glomerulonephritis. In David Harris (Eds.), Clinical Cases in Kidney Disease, (pp. 192-204). Australia: McGraw Hill.
  • Rangan, G. (2008). Renal Mass. In David Harris (Eds.), Clinical Cases in Kidney Disease, (pp. 49-62). Australia: McGraw Hill.

Journals

  • Chua, T., Prasad, N., Rangan, G., Allman-Farinelli, M., Rangan, A. (2016). A systematic review to determine the most effective interventions to increase water intake. Nephrology, in press. [More Information]
  • Rangan, G. (2016). C5b-9 does not mediate tubulointerstitial injury in experimental acute glomerular disease characterized by selective proteinuria. World Journal of Nephrology, 5(3), 288-299. [More Information]
  • Tong, A., Tunnicliffe, D., Lopez-Vargas, P., Mallett, A., Patel, C., Savige, J., Campbell, K., Patel, M., Tchan, M., Alexander, S., Lee, V., Craig, J., Rangan, G., et al (2016). Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney disease. Nephrology, 21(2), 122-132. [More Information]
  • Rangan, G., Alexander, S., Campbell, K., Lee, V., Lopez-Vargas, P., Mai, J., Mallett, A., Patel, C., Patel, M., Tchan, M., Tong, A., Tunnicliffe, D., et al (2016). KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology, 21(8), 705-716. [More Information]
  • Tong, A., Rangan, G., Ruospo, M., Saglimbene, V., Strippoli, G., Palmer, S., Tunnicliffe, D., Craig, J. (2015). A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research. Nephrology, Dialysis, Transplantation, 30(5), 790-800. [More Information]
  • Alexander, S., Rangan, G., Tchan, M., McCarthy, W., Mallett, A., Patel, C., Maier, A., McGaughran, J., Gabbett, M., Takasato, M., et al (2015). A protocol for the identification and validation of novel genetic causes of kidney disease. BMC Nephrology, 16(1), 1-10. [More Information]
  • Rangan, G., Lopez-Vargas, P., Nankivell (Nankievell), B., Tchan, M., Tong, A., Tunnicliffe, D., Savige, J. (2015). Autosomal Dominant Polycystic Kidney Disease: A Path Forward. Seminars in Nephrology, 35(6), 524-537. [More Information]
  • Ta, M., Liuwantara, D., Rangan, G. (2015). Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor-κB activity in autosomal dominant polycystic kidney disease cells. BMC Nephrology, 16(1), 1-13. [More Information]
  • Savige, J., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Kidney Disease Guideline: Management of Chronic Pain. Seminars in Nephrology, 35(6), 607-611.e3. [More Information]
  • Campbell, K., Rangan, G., Lopez-Vargas, P., Tong, A. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Management. Seminars in Nephrology, 35(6), 572-581.e17. [More Information]
  • Tchan, M., Savige, J., Patel, C., Mallett, A., Tong, A., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis. Seminars in Nephrology, 35(6), 545-549.e2. [More Information]
  • Patel, C., Tchan, M., Savige, J., Mallett, A., Tong, A., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic Counseling. Seminars in Nephrology, 35(6), 550-556.e1. [More Information]
  • Lee, V., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of End-Stage Kidney Disease. Seminars in Nephrology, 35(6), 595-602.e12. [More Information]
  • Lee, V., Dexter, M., Mai, J., Vladica, P., Lopez-Vargas, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Intracranial Aneurysms. Seminars in Nephrology, 35(6), 612-617.e20. [More Information]
  • Savige, J., Mallett, A., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease. Seminars in Nephrology, 35(6), 618-622.E5. [More Information]
  • Mallett, A., Patel, M., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Renal Stone Disease. Seminars in Nephrology, 35(6), 603-606 e3. [More Information]
  • Mai, J., Lee, V., Lopez-Vargas, P., Vladica, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Monitoring Disease Progression. Seminars in Nephrology, 35(6), 565-571.e18. [More Information]
  • Mallett, A., Lee, V., Mai, J., Lopez-Vargas, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management. Seminars in Nephrology, 35(6), 582-589.e17. [More Information]
  • Tong, A., Mallett, A., Lopez-Vargas, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Psychosocial Care. Seminars in Nephrology, 35(6), 590-594.e5. [More Information]
  • Rangan, G., Lee, V., Alexander, S., Patel, C., Tunnicliffe, D., Vladica, P. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Screening for Polycystic Kidney Disease. Seminars in Nephrology, 35(6), 557-564.e6. [More Information]
  • Crawford, S., Chen, S., Halliday, C., Rangan, G., Gottlieb, T., Reid, A. (2015). Microsphaeropsis arundinis skin and soft tissue infection in renal transplant recipients: three case reports and a review of the literature. Transplant Infectious Disease (Print), 17(6), 915-920. [More Information]
  • Bose, B., Badve, S., Hiremath, S., Boudville, N., Brown, F., Cass, A., de Zoysa, J., Fassett, R., Faull, R., Harris, D., Perkovic, V., Rangan, G., et al (2014). Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrology, Dialysis, Transplantation, 29(2), 406-413. [More Information]
  • Succar, L., Lai-Kwon, J., Nikolic-Paterson, D., Rangan, G. (2014). Induction monotherapy with sirolimus has selected beneficial effects on glomerular and tubulointersititial injury in nephrotoxic serum nephritis. International Journal of Nephrology and Renovascular Disease, 7, 303-313. [More Information]
  • Chaudhry, R., Rangan, G. (2014). Levels of haloacetic acids in tap water in an urban Australian city and its relevance to autosomal dominant polycystic kidney disease. Kidney International, 85(6), 1471-1471. [More Information]
  • Rangan, G., Nankivell (Nankievell), B. (2014). Management of autosomal dominant polycystic kidney disease. Medicine Today, 15(6), 16-27.
  • McDonald, S., Rangan, G. (2014). Polycystic kidney disease: Progression of polycystic kidney disease-a lack of progress? Nature Reviews Nephrology, 10(9), 489-491. [More Information]
  • Ta, M., Rao, P., Korgaonkar, M., Foster, S., Peduto, A., Harris, D., Rangan, G. (2014). Pyrrolidine dithiocarbamate reduces the progression of total kidney volume and cyst enlargement in experimental polycystic kidney disease. Physiological Reports, 2(12), 1-15. [More Information]
  • Myint, T., Rangan, G., Webster, A. (2014). Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta -analysis of randomized trials. Nephrology, 19(4), 217-226. [More Information]
  • Chapman, J., Rangan, G. (2013). Are Nonesterified Fatty Acids Protective in Chronic Allograft Nephropathy? Transplantation, 95(11), 1313-1314. [More Information]
  • Rangan, G., Schwensen, K., Foster, S., Korgaonkar, M., Peduto, A., Harris, D. (2013). Chronic effects of dietary Vitamin D deficiency without increased calcium supplementation on the progression of experimental polycystic kidney disease. American Journal of Physiology: Renal Physiology, 305(4), F574-F582. [More Information]
  • Ta, M., Rao, P., Korgaonkar, M., Foster, S., Peduto, A., Harris, D., Rangan, G. (2013). Pyrrolidine Dithiocarbamate Attenuates Kidney Enlargement in Experimental Polycystic Kidney Disease. Nephrology, 18(Supp. 1), 37-37.
  • Rangan, G., Harris, D. (2013). Rationale and Design of an Observational Study to Determine the Effects of Cholecalciferol on Hypertension, Proteinuria and Urinary MCP-1 in ADPKD. Current Hypertension Reviews, 9(2), 115-120. [More Information]
  • Ta, M., Harris, D., Rangan, G. (2013). Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology, 18(5), 317-330. [More Information]
  • Badve, S., Brown, F., Hawley, C., Johnson, D., Kanellis, J., Rangan, G., Perkovic, V. (2011). Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nature Reviews Nephrology, 7(5), 295-300. [More Information]
  • Schwensen, K., Burgess, J., Graf, N., Alexander, S., Harris, D., Phillips, J., Rangan, G. (2011). Early Cyst Growth Is Associated with the Increased Nuclear Expression of Cyclin D1/Rb Protein in an Autosomal-Recessive Polycystic Kidney Disease Rat Model. Nephron Experimental Nephrology, 117(4), e93-e103. [More Information]
  • Rangan, G., Burgess, J., Schwensen, K., Harris, D. (2010). Polycystic kidney disease - Part 1. Medical Observer, 19 March, 27-29.
  • Rangan, G., Burgess, J., Schwensen, K., Harris, D. (2010). Polycystic kidney disease - Part 2. Medical Observer, 26 March, 29-31.
  • Zheng, G., Lyons, J., Tan, T., Wang, Y., Hsu, T., Min, D., Succar, L., Rangan, G., Hu, M., Henderson, B., Alexander, S., Harris, D. (2009). Disruption of E-Cadherin by Matrix Metalloproteinase Directly Mediates Epithelial-Mesenchymal Transition Downstream of Transforming Growth Factor-{beta}1 in Renal Tubular Epithelial Cells. The American Journal of Pathology, 175(2), 580-591. [More Information]
  • Rangan, G., Wang, Y., Harris, D. (2009). NF-kappaB signalling in chronic kidney disease. Frontiers in Bioscience, 14, 3496-3522. [More Information]
  • Rangan, G., Nguyen, T., Mainra, R., Succar, L., Schwensen, K., Burgess, J., Ho, K. (2009). Therapeutic role of sirolimus in non-transplant kidney disease. Pharmacology and Therapeutics, 123(2), 187-206. [More Information]
  • Rangan, G., Tesch, G. (2007). Quantification of renal pathology by image analysis (Methods in Renal Research). Nephrology, 12(6), 553-558. [More Information]
  • Rangan, G., Coombes, J. (2007). Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. Nephrology, Dialysis, Transplantation, 22(8), 2175-2182. [More Information]
  • Phillips, J., Hopwood, D., Loxley, R., Ghatora, K., Coombes, J., Tan, Y., Harrison, J., McKitrick, D., Holobotvskyy, V., Arnolda, L., Rangan, G. (2007). Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Kidney and Blood Pressure Research, 30(3), 129-144.
  • Lee, V., Wang, Y., Qin, X., Wang, Y., Zheng, G., Mahajan, D., Coombes, J., Rangan, G., Alexander, S., Harris, D. (2006). Adriamycin nephropathy in severe combined immunodeficient (SCID) mice. Nephrology, Dialysis, Transplantation. [More Information]
  • Rangan, G., Kan, G., Steer, J., Dogra, G., Croft, K., Rhodes, H., Woodroffe, A., Joyce, D. (2006). Altered expression of nuclear factor-kappa B in peripheral blood mononuclear cells in chronic haemodialysis patients. Nephrology, Dialysis, Transplantation, 21(4), 1137-1139.
  • Zheng, G., Wang, Y., XIANG, S., Tay, Y., Wu, H., Watson, D., Coombes, J., Rangan, G., Alexander, S., Harris, D. (2006). DNA vaccination with CCL2 DNA modified by the addition of an adjuvant epitope protects against "nonimmune" toxic renal injury. Journal of the American Society of Nephrology, 17(2), 465-474. [More Information]
  • Zhu, G., Wang, Y., Wang, J., Tay, Y., Yung, T., Rangan, G., Harris, D. (2006). Significance of CD25 positive cells and macrophages in noncrescentic IgA nephropathy. Renal Failure, 28(3), 229-235. [More Information]
  • Rangan, G. (2006). Sirolimus-associated proteinuria and renal dysfunction. Drug Safety, 29(12), 1153-1161. [More Information]
  • Geevasinga, N., Kairaitis, L., Rangan, G., Coleman, P. (2005). Acute interstitial nephritis secondary to esomeprazole. Medical Journal of Australia, 182(5). [More Information]
  • Rangan, G., Kan, G., Steer, J., Dogra, G., Croft, K., Rhodes, H., Woodroffe, A., Joyce, D. (2005). Altered expression of nuclear factor-{kappa}B in peripheral blood mononuclear cells in chronic haemodialysis patients. Nephrology, Dialysis, Transplantation, 21, 1137-9. [More Information]
  • Rangan, G., Pippin, J., Coombes, J., Couser, W. (2005). C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria. Kidney International, 67(2), 492-503. [More Information]
  • Tay, Y., Wang, Y., Kairaitis, L., Rangan, G., Zhang, C., Harris, D. (2005). Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney International, 68(1), 391-398. [More Information]
  • Rangan, G., Wang, Y., Tay, Y., Harris, D. (2005). Differential effects of albumin on cytokine gene expression in proximal tubular epithelial cells. Nephrology, Dialysis, Transplantation, 20(5), 1013-1014.
  • Rangan, G., Tay, Y., Harris, D. (2005). Differential effects of albumin on cytokine gene expression in proximal tubular epithelial cells. Nephrology, Dialysis, Transplantation, 20(5), 1013-4. [More Information]
  • Rangan, G., Wang, Y., Harris, D., Tay, Y., Coombes, J. (2005). Effect of nephrotoxins on tubulointerstitial injury and NF-kappaB activation in Adriamycin nephropathy. Renal Failure, 27(5), 609-14. [More Information]
  • Wang, Y., Mahajan, D., Tay, Y., Bao, B., Spicer, T., Kairaitis, L., Rangan, G., Harris, D. (2005). Partial depletion of macrophages by ED7 reduces renal injury in Adriamycin nephropathy. Nephrology, 10(5), 470-7. [More Information]
  • Liddle, C., Rangan, G., Coombes, J., Mreich, E. (2005). Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney International. [More Information]
  • Harris, D., Rangan, G. (2005). Retardation of kidney failure -- applying principles to practice. Annals of the Academy of Medicine, Singapore (AAMS), 34(1), 16-23. [More Information]
  • Rangan, G., Pippin, J., Couser, W. (2004). C5B-9 Regulates Peritubular Myofibroblast Accumulation In Experimental Focal Segmental Glomerulosclerosis. Kidney International, 66(5), 1838-1848.
  • Rangan, G., Harris, D. (2003). A blast from the mast? Kidney International, 64(3), 1134-1135.

Conferences

  • Foster, S., Korgaonkar, M., Rangan, G., Schwensen, K., Peduto, A. (2010). Changes in kidney volume in experimental Polycystic Kidney Disease (PKD) quantified by a clinical 3T MR Scanner. ISMRM/SMRT Annual Meeting.
  • Schwensen, K., Foster, S., Korgaonkar, M., Peduto, A., Harris, D., Rangan, G. (2010). Sequential assessment of total kidney volume (TKV) in experimental autosomal recessive Polycystic Kidney Disease (ARPKD) using a clinical 3T scanner. 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology.
  • Schwensen, K., Foster, S., Korgaonkar, M., Peduto, A., Harris, D., Rangan, G. (2010). Sirolimus (S) reduces kidney enlargement but does not improve cystic microarchitecture in established Polycystic Kidney Disease (PKD). 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology.

2016

  • Chua, T., Prasad, N., Rangan, G., Allman-Farinelli, M., Rangan, A. (2016). A systematic review to determine the most effective interventions to increase water intake. Nephrology, in press. [More Information]
  • Rangan, G. (2016). C5b-9 does not mediate tubulointerstitial injury in experimental acute glomerular disease characterized by selective proteinuria. World Journal of Nephrology, 5(3), 288-299. [More Information]
  • Tong, A., Tunnicliffe, D., Lopez-Vargas, P., Mallett, A., Patel, C., Savige, J., Campbell, K., Patel, M., Tchan, M., Alexander, S., Lee, V., Craig, J., Rangan, G., et al (2016). Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney disease. Nephrology, 21(2), 122-132. [More Information]
  • Rangan, G., Alexander, S., Campbell, K., Lee, V., Lopez-Vargas, P., Mai, J., Mallett, A., Patel, C., Patel, M., Tchan, M., Tong, A., Tunnicliffe, D., et al (2016). KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology, 21(8), 705-716. [More Information]

2015

  • Tong, A., Rangan, G., Ruospo, M., Saglimbene, V., Strippoli, G., Palmer, S., Tunnicliffe, D., Craig, J. (2015). A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research. Nephrology, Dialysis, Transplantation, 30(5), 790-800. [More Information]
  • Alexander, S., Rangan, G., Tchan, M., McCarthy, W., Mallett, A., Patel, C., Maier, A., McGaughran, J., Gabbett, M., Takasato, M., et al (2015). A protocol for the identification and validation of novel genetic causes of kidney disease. BMC Nephrology, 16(1), 1-10. [More Information]
  • Rangan, G., Lopez-Vargas, P., Nankivell (Nankievell), B., Tchan, M., Tong, A., Tunnicliffe, D., Savige, J. (2015). Autosomal Dominant Polycystic Kidney Disease: A Path Forward. Seminars in Nephrology, 35(6), 524-537. [More Information]
  • Ta, M., Liuwantara, D., Rangan, G. (2015). Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor-κB activity in autosomal dominant polycystic kidney disease cells. BMC Nephrology, 16(1), 1-13. [More Information]
  • Savige, J., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Kidney Disease Guideline: Management of Chronic Pain. Seminars in Nephrology, 35(6), 607-611.e3. [More Information]
  • Campbell, K., Rangan, G., Lopez-Vargas, P., Tong, A. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Management. Seminars in Nephrology, 35(6), 572-581.e17. [More Information]
  • Tchan, M., Savige, J., Patel, C., Mallett, A., Tong, A., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis. Seminars in Nephrology, 35(6), 545-549.e2. [More Information]
  • Patel, C., Tchan, M., Savige, J., Mallett, A., Tong, A., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic Counseling. Seminars in Nephrology, 35(6), 550-556.e1. [More Information]
  • Lee, V., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of End-Stage Kidney Disease. Seminars in Nephrology, 35(6), 595-602.e12. [More Information]
  • Lee, V., Dexter, M., Mai, J., Vladica, P., Lopez-Vargas, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Intracranial Aneurysms. Seminars in Nephrology, 35(6), 612-617.e20. [More Information]
  • Savige, J., Mallett, A., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease. Seminars in Nephrology, 35(6), 618-622.E5. [More Information]
  • Mallett, A., Patel, M., Tunnicliffe, D., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Renal Stone Disease. Seminars in Nephrology, 35(6), 603-606 e3. [More Information]
  • Mai, J., Lee, V., Lopez-Vargas, P., Vladica, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Monitoring Disease Progression. Seminars in Nephrology, 35(6), 565-571.e18. [More Information]
  • Mallett, A., Lee, V., Mai, J., Lopez-Vargas, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management. Seminars in Nephrology, 35(6), 582-589.e17. [More Information]
  • Tong, A., Mallett, A., Lopez-Vargas, P., Rangan, G. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Psychosocial Care. Seminars in Nephrology, 35(6), 590-594.e5. [More Information]
  • Rangan, G., Lee, V., Alexander, S., Patel, C., Tunnicliffe, D., Vladica, P. (2015). KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Screening for Polycystic Kidney Disease. Seminars in Nephrology, 35(6), 557-564.e6. [More Information]
  • Crawford, S., Chen, S., Halliday, C., Rangan, G., Gottlieb, T., Reid, A. (2015). Microsphaeropsis arundinis skin and soft tissue infection in renal transplant recipients: three case reports and a review of the literature. Transplant Infectious Disease (Print), 17(6), 915-920. [More Information]

2014

  • Bose, B., Badve, S., Hiremath, S., Boudville, N., Brown, F., Cass, A., de Zoysa, J., Fassett, R., Faull, R., Harris, D., Perkovic, V., Rangan, G., et al (2014). Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrology, Dialysis, Transplantation, 29(2), 406-413. [More Information]
  • Succar, L., Lai-Kwon, J., Nikolic-Paterson, D., Rangan, G. (2014). Induction monotherapy with sirolimus has selected beneficial effects on glomerular and tubulointersititial injury in nephrotoxic serum nephritis. International Journal of Nephrology and Renovascular Disease, 7, 303-313. [More Information]
  • Chaudhry, R., Rangan, G. (2014). Levels of haloacetic acids in tap water in an urban Australian city and its relevance to autosomal dominant polycystic kidney disease. Kidney International, 85(6), 1471-1471. [More Information]
  • Rangan, G., Nankivell (Nankievell), B. (2014). Management of autosomal dominant polycystic kidney disease. Medicine Today, 15(6), 16-27.
  • McDonald, S., Rangan, G. (2014). Polycystic kidney disease: Progression of polycystic kidney disease-a lack of progress? Nature Reviews Nephrology, 10(9), 489-491. [More Information]
  • Ta, M., Rao, P., Korgaonkar, M., Foster, S., Peduto, A., Harris, D., Rangan, G. (2014). Pyrrolidine dithiocarbamate reduces the progression of total kidney volume and cyst enlargement in experimental polycystic kidney disease. Physiological Reports, 2(12), 1-15. [More Information]
  • Myint, T., Rangan, G., Webster, A. (2014). Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta -analysis of randomized trials. Nephrology, 19(4), 217-226. [More Information]

2013

  • Chapman, J., Rangan, G. (2013). Are Nonesterified Fatty Acids Protective in Chronic Allograft Nephropathy? Transplantation, 95(11), 1313-1314. [More Information]
  • Rangan, G., Schwensen, K., Foster, S., Korgaonkar, M., Peduto, A., Harris, D. (2013). Chronic effects of dietary Vitamin D deficiency without increased calcium supplementation on the progression of experimental polycystic kidney disease. American Journal of Physiology: Renal Physiology, 305(4), F574-F582. [More Information]
  • Ta, M., Rao, P., Korgaonkar, M., Foster, S., Peduto, A., Harris, D., Rangan, G. (2013). Pyrrolidine Dithiocarbamate Attenuates Kidney Enlargement in Experimental Polycystic Kidney Disease. Nephrology, 18(Supp. 1), 37-37.
  • Rangan, G., Harris, D. (2013). Rationale and Design of an Observational Study to Determine the Effects of Cholecalciferol on Hypertension, Proteinuria and Urinary MCP-1 in ADPKD. Current Hypertension Reviews, 9(2), 115-120. [More Information]
  • Ta, M., Harris, D., Rangan, G. (2013). Role of interstitial inflammation in the pathogenesis of polycystic kidney disease. Nephrology, 18(5), 317-330. [More Information]

2012

  • Sud, K., Rangan, G. (2012). Peritonitis and Exit-Site Infections. In David Harris, Grahame Elder, Lukas Kairaitis, Gopala Rangan (Eds.), Pocket Guide to Clinical Dialysis, (pp. 245-255). Sydney, Australia: McGraw Hill.
  • Harris, D., Elder, G., Kairaitis, L., Rangan, G. (2012). Pocket Guide to Clinical Dialysis. Sydney, Australia: McGraw Hill.

2011

  • Badve, S., Brown, F., Hawley, C., Johnson, D., Kanellis, J., Rangan, G., Perkovic, V. (2011). Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nature Reviews Nephrology, 7(5), 295-300. [More Information]
  • Schwensen, K., Burgess, J., Graf, N., Alexander, S., Harris, D., Phillips, J., Rangan, G. (2011). Early Cyst Growth Is Associated with the Increased Nuclear Expression of Cyclin D1/Rb Protein in an Autosomal-Recessive Polycystic Kidney Disease Rat Model. Nephron Experimental Nephrology, 117(4), e93-e103. [More Information]
  • Succar, L., Harris, D., Rangan, G. (2011). Role of the Mammalian Target of Rapamycin (mTOR) Signalling Pathway in Podocytes in Glomerular Disease. In Sharma S. Prabhakar (Eds.), An Update on Glomerulopathies - Etiology and Pathogenesis, (pp. 183-202). Rijeka, Croatia: InTech Publishers.

2010

  • Foster, S., Korgaonkar, M., Rangan, G., Schwensen, K., Peduto, A. (2010). Changes in kidney volume in experimental Polycystic Kidney Disease (PKD) quantified by a clinical 3T MR Scanner. ISMRM/SMRT Annual Meeting.
  • Rangan, G., Burgess, J., Schwensen, K., Harris, D. (2010). Polycystic kidney disease - Part 1. Medical Observer, 19 March, 27-29.
  • Rangan, G., Burgess, J., Schwensen, K., Harris, D. (2010). Polycystic kidney disease - Part 2. Medical Observer, 26 March, 29-31.
  • Schwensen, K., Foster, S., Korgaonkar, M., Peduto, A., Harris, D., Rangan, G. (2010). Sequential assessment of total kidney volume (TKV) in experimental autosomal recessive Polycystic Kidney Disease (ARPKD) using a clinical 3T scanner. 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology.
  • Schwensen, K., Foster, S., Korgaonkar, M., Peduto, A., Harris, D., Rangan, G. (2010). Sirolimus (S) reduces kidney enlargement but does not improve cystic microarchitecture in established Polycystic Kidney Disease (PKD). 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology.

2009

  • Zheng, G., Lyons, J., Tan, T., Wang, Y., Hsu, T., Min, D., Succar, L., Rangan, G., Hu, M., Henderson, B., Alexander, S., Harris, D. (2009). Disruption of E-Cadherin by Matrix Metalloproteinase Directly Mediates Epithelial-Mesenchymal Transition Downstream of Transforming Growth Factor-{beta}1 in Renal Tubular Epithelial Cells. The American Journal of Pathology, 175(2), 580-591. [More Information]
  • Rangan, G., Wang, Y., Harris, D. (2009). NF-kappaB signalling in chronic kidney disease. Frontiers in Bioscience, 14, 3496-3522. [More Information]
  • Rangan, G., Nguyen, T., Mainra, R., Succar, L., Schwensen, K., Burgess, J., Ho, K. (2009). Therapeutic role of sirolimus in non-transplant kidney disease. Pharmacology and Therapeutics, 123(2), 187-206. [More Information]

2008

  • Rangan, G. (2008). Haematuria. In David Harris (Eds.), Clinical Cases in Kidney Disease, (pp. 63-75). Australia: McGraw Hill.
  • Rangan, G., Succar, L. (2008). Rapidly Progressive Glomerulonephritis. In David Harris (Eds.), Clinical Cases in Kidney Disease, (pp. 192-204). Australia: McGraw Hill.
  • Rangan, G. (2008). Renal Mass. In David Harris (Eds.), Clinical Cases in Kidney Disease, (pp. 49-62). Australia: McGraw Hill.

2007

  • Rangan, G., Tesch, G. (2007). Quantification of renal pathology by image analysis (Methods in Renal Research). Nephrology, 12(6), 553-558. [More Information]
  • Rangan, G., Coombes, J. (2007). Renoprotective effects of sirolimus in non-immune initiated focal segmental glomerulosclerosis. Nephrology, Dialysis, Transplantation, 22(8), 2175-2182. [More Information]
  • Phillips, J., Hopwood, D., Loxley, R., Ghatora, K., Coombes, J., Tan, Y., Harrison, J., McKitrick, D., Holobotvskyy, V., Arnolda, L., Rangan, G. (2007). Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Kidney and Blood Pressure Research, 30(3), 129-144.

2006

  • Lee, V., Wang, Y., Qin, X., Wang, Y., Zheng, G., Mahajan, D., Coombes, J., Rangan, G., Alexander, S., Harris, D. (2006). Adriamycin nephropathy in severe combined immunodeficient (SCID) mice. Nephrology, Dialysis, Transplantation. [More Information]
  • Rangan, G., Kan, G., Steer, J., Dogra, G., Croft, K., Rhodes, H., Woodroffe, A., Joyce, D. (2006). Altered expression of nuclear factor-kappa B in peripheral blood mononuclear cells in chronic haemodialysis patients. Nephrology, Dialysis, Transplantation, 21(4), 1137-1139.
  • Zheng, G., Wang, Y., XIANG, S., Tay, Y., Wu, H., Watson, D., Coombes, J., Rangan, G., Alexander, S., Harris, D. (2006). DNA vaccination with CCL2 DNA modified by the addition of an adjuvant epitope protects against "nonimmune" toxic renal injury. Journal of the American Society of Nephrology, 17(2), 465-474. [More Information]
  • Zhu, G., Wang, Y., Wang, J., Tay, Y., Yung, T., Rangan, G., Harris, D. (2006). Significance of CD25 positive cells and macrophages in noncrescentic IgA nephropathy. Renal Failure, 28(3), 229-235. [More Information]
  • Rangan, G. (2006). Sirolimus-associated proteinuria and renal dysfunction. Drug Safety, 29(12), 1153-1161. [More Information]

2005

  • Geevasinga, N., Kairaitis, L., Rangan, G., Coleman, P. (2005). Acute interstitial nephritis secondary to esomeprazole. Medical Journal of Australia, 182(5). [More Information]
  • Rangan, G., Kan, G., Steer, J., Dogra, G., Croft, K., Rhodes, H., Woodroffe, A., Joyce, D. (2005). Altered expression of nuclear factor-{kappa}B in peripheral blood mononuclear cells in chronic haemodialysis patients. Nephrology, Dialysis, Transplantation, 21, 1137-9. [More Information]
  • Harris, D., Elder, G., Kairaitis, L., Rangan, G. (2005). Basic Clinical Dialysis. Sydney: McGraw-Hill, Medical Pub. Division.
  • Rangan, G., Pippin, J., Coombes, J., Couser, W. (2005). C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria. Kidney International, 67(2), 492-503. [More Information]
  • Tay, Y., Wang, Y., Kairaitis, L., Rangan, G., Zhang, C., Harris, D. (2005). Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney International, 68(1), 391-398. [More Information]
  • Rangan, G., Wang, Y., Tay, Y., Harris, D. (2005). Differential effects of albumin on cytokine gene expression in proximal tubular epithelial cells. Nephrology, Dialysis, Transplantation, 20(5), 1013-1014.
  • Rangan, G., Tay, Y., Harris, D. (2005). Differential effects of albumin on cytokine gene expression in proximal tubular epithelial cells. Nephrology, Dialysis, Transplantation, 20(5), 1013-4. [More Information]
  • Rangan, G., Wang, Y., Harris, D., Tay, Y., Coombes, J. (2005). Effect of nephrotoxins on tubulointerstitial injury and NF-kappaB activation in Adriamycin nephropathy. Renal Failure, 27(5), 609-14. [More Information]
  • Wang, Y., Mahajan, D., Tay, Y., Bao, B., Spicer, T., Kairaitis, L., Rangan, G., Harris, D. (2005). Partial depletion of macrophages by ED7 reduces renal injury in Adriamycin nephropathy. Nephrology, 10(5), 470-7. [More Information]
  • Liddle, C., Rangan, G., Coombes, J., Mreich, E. (2005). Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney International. [More Information]
  • Harris, D., Rangan, G. (2005). Retardation of kidney failure -- applying principles to practice. Annals of the Academy of Medicine, Singapore (AAMS), 34(1), 16-23. [More Information]

2004

  • Rangan, G., Pippin, J., Couser, W. (2004). C5B-9 Regulates Peritubular Myofibroblast Accumulation In Experimental Focal Segmental Glomerulosclerosis. Kidney International, 66(5), 1838-1848.

2003

  • Rangan, G., Harris, D. (2003). A blast from the mast? Kidney International, 64(3), 1134-1135.

To update your profile click here. For support on your academic profile contact .